In about half of the reporting countries in the WHO European Region, at least half of the samples of 2 common hospital bacteria, Klebsiella pneumoniae and Acinetobacter, taken from patients with serious infections were resistant to key antibiotics. That is according to a joint analysis published today by WHO/Europe and European Centre for Disease Prevention and Control (ECDC).
Klebsiella pneumoniae is a common hospital bacterium that can cause serious bloodstream infections. In 21 of the 43 countries that reported 2025 data on it, half or more of the samples tested were resistant to third-generation cephalosporins. The analysis notes that when these antibiotics can no longer be relied on, doctors increasingly turn to carbapenems, antibiotics that work against a wider range of bacteria, although other options sometimes exist. In some countries, resistance to carbapenems is also high. In 10 of the 43 countries, half or more of Klebsiella pneumoniae bacteria resisted carbapenems. For Acinetobacter, another bacterium that spreads in hospitals, the same was true in 21 of 38 reporting countries.
“In many countries in our Region, the antibiotics doctors usually reach for first are failing against serious hospital infections,” said Dr Marc-Alain Widdowson, Programme Manager, Health Security Division, WHO/Europe. “So doctors turn to carbapenems, stronger drugs normally kept for the most serious cases. When those stop working too, what’s left is mostly a small group of last-resort drugs that are often expensive and not available in every country. Each time one of these lines of defence falls, patients move closer to having no good options. That matters, because people whose first antibiotic doesn’t work against their infection are more likely to die in hospital.”
Two of three EU targets further out of reach
In 2023, the European Union (EU) set 3 targets to reduce bloodstream infections caused by resistant bacteria by 2030, using 2019 as the starting point. Two of them are now further from being met than in 2019. Instead of achieving the target of a 5% fall in infections with Klebsiella pneumoniae resistant to carbapenems, they rose by an estimated 72% between 2019 and 2025. Infections with E. coli resistant to third-generation cephalosporins, a group of commonly used antibiotics, were set a target of a 10% fall. Instead, they rose by an estimated 16.4%. E. coli is one of the most common causes of bloodstream infections in the EU. The third target, a 15% reduction in methicillin-resistant Staphylococcus aureus (MRSA), has already been met: the estimated fall in infections was 19% between 2019 and 2025; but rates of infection have risen in the last 2 years, which may put the target at risk.
There is some good news across the EU. The estimated rate of bloodstream infections with resistant Acinetobacter has almost halved since the high levels seen in 2021, during the COVID-19 pandemic.
Gaps in what countries can see
Many countries still cannot see the full scale of the problem. Of the 51 countries with data, 16 (31%) still collect resistance data without a standardized national approach and national coordination. In hospitals where few blood samples are taken to identify the bacteria behind an infection, doctors often have to choose an antibiotic without knowing which will work. The samples that are taken come mostly from the sickest patients, so the national picture is incomplete.
For patients, this raises the risk of starting treatment on a drug that will not work. For health systems, it means planning half-blind: without reliable data, countries cannot tell where resistance is spreading or whether their efforts to stop it are working. Better testing would help on both fronts, giving patients the right drug sooner and countries a clearer view of the threat.
Plans need funding
Almost every country in the Region (94%) reports having a national action plan on antimicrobial resistance or revising one. But only 40% report carrying it out with funding in place and regular checks on progress.
“Nearly every country in our Region has a plan to tackle antimicrobial resistance. Far fewer have the money and follow-through to make it work, and a plan on paper doesn’t stop an infection on a hospital ward,” concluded Dr Widdowson. “Strict infection control in hospitals, careful use of antibiotics, labs that can spot resistant bacteria quickly, and the right drugs in the right place do. The fall in MRSA bloodstream infections in the EU since 2019 shows that these trends can be reversed.”
WHO/Europe is calling on countries in the Region to:
- fund and carry out their national action plans on antimicrobial resistance, with regular checks on progress;
- strengthen infection prevention and control in hospitals, so resistant bacteria do not spread between patients;
- use antibiotics carefully, so carbapenems and last-resort drugs are kept for patients who need them;
- invest in laboratories, including national reference laboratories that can identify how bacteria resist carbapenems, and in more routine blood cultures so doctors know which drugs will work; and
- make sure last-resort antibiotics are available where patients need them.
About the data
- The report brings together 2025 data from 2 networks. The European Antimicrobial Resistance Surveillance Network (EARS-Net), coordinated by the ECDC, covers all 30 EU/European Economic Area (EEA) countries. The Central Asian and European Surveillance of Antimicrobial Resistance (CAESAR) network, coordinated by WHO/Europe, covers 17 countries in the rest of the Region. Tajikistan reported data for the first time in 2025.
- The data come from bacteria found in blood and cerebrospinal fluid. The networks use compatible methods, but national systems differ, so comparisons between countries need caution.
- Region-wide figures cover the countries that reported each bacterium–antibiotic combination (for example 43 countries for Klebsiella pneumoniae, 38 for Acinetobacter), not all 53 Member States.
- Key antibiotics refers to third-generation cephalosporins for Klebsiella pneumoniae and E. coli, and carbapenems for Acinetobacter. Carbapenems are a class of broad-spectrum antibiotics used for serious infections when other drugs fail. WHO classifies a small group of last-resort drugs as “reserve” antibiotics.
- The EU targets come from the 2023 “Council Recommendation on stepping up EU actions to combat antimicrobial resistance in a One Health approach”. They apply to the EU, with 2019 as the baseline year: cuts of 15% for MRSA, 10% for third-generation cephalosporin-resistant E. coli and 5% for carbapenem-resistant Klebsiella pneumoniae bloodstream infections by 2030.
- WHO/Europe, with the London School of Economics and support from the Novo Nordisk Foundation, is finalizing an Antimicrobial Resistance Accountability Index, piloted in 6 countries in 2026. With EU4Health funding, WHO/Europe is also reviewing antibiotic stewardship and infection prevention practices in hospitals in 6 countries, with coaching to follow in 2027.
- "Resistant” means that laboratory testing showed the antibiotic is unlikely to work against that bacterium. The report measures laboratory results, not treatment outcomes.



